AI in Drug Discovery Market (2026 - 2035)

AI in Drug Discovery Market Research Report By Application (Target Identification, Lead Optimization, Drug Repurposing, Clinical Trials, Preclinical Testing), By Technology (Machine Learning, Natural Language Processing, Deep Learning, Knowledge Graphs, Robotic Process Automation), By Workflow (Data Mining, Predictive Modeling, Clinical Data Management, Assay Development), By End User (Pharmaceutical Companies, Biotechnology Firms, Research Institutions, Academic Institutions) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Industry Forecast to 2035
ID: MRFR/Pharma/7918-CR
200 Pages
Kinjoll Dey, Vikita Thakur
Last Updated: July 28, 2026
AI in Drug Discovery Market
Market Size
Forecast Period2026-2035
CAGR (2026-2035)23.9%
2025 Market SizeUSD 2.81 Billion
2035 Market SizeUSD 23.95 Billion
Key Players
Insilico Medicine
Schrödinger
Recursion Pharmaceuticals
Exscientia
BenevolentAI
Atomwise
Trends
  • Escalating Drug Development Costs
  • Exponential Growth in Biomedical Data
  • Government AI-Healthcare Funding Programs
Opportunities
  • AI-Powered Rare Disease Drug Discovery
  • Emerging Market Expansion in India and China
  • AI-as-a-Service Platforms for Mid-Tier Pharma
Request Free Sample

AI in Drug Discovery Market Summary

The AI in Drug Discovery Market was valued at USD 2.81 billion in 2025 and is projected to grow from USD 3.48 billion in 2026 to USD 23.95 billion by 2035, registering a CAGR of 23.9% during the forecast period. This expansion is fueled by a pharmaceutical industry spending upwards of USD 2.3 billion annually on AI-enabled R&D platforms, and by regulatory signals from the U.S. FDA, which accepted over 300 AI-assisted submissions during 2023–2024 alone [1]. The cost of bringing a single drug to market now exceeds USD 2.6 billion on average, and the AI in Drug Discovery Market is positioned as the most direct answer to this unsustainable trajectory [2].

Traditional high-throughput screening and manual lead optimization workflows are giving way to deep-learning-driven virtual screening engines and generative chemistry platforms. Pharma giants committed more than USD 5.8 billion in AI-pharma partnerships between 2022 and 2024, with Pfizer, Roche, and AstraZeneca each building dedicated in-house AI labs [3]. Computational drug screening capabilities have matured significantly, enabling preclinical candidate selection in months rather than years [4].

North America commands approximately 42% of the AI in Drug Discovery Market, driven by the density of biotech startups and NIH funding pipelines. Asia-Pacific is the fastest-growing region, expanding at a CAGR of 27.4%, powered by China's AI-pharma industrial policy and India's growing CRO ecosystem. Europe holds the second-largest share at roughly 28%, anchored by the UK's life-sciences superpower agenda and France's Health Data Hub initiative [5]. The decade ahead will reshape how therapies reach patients.

 

Key Report Takeaways

• By Component

  • Software solutions account for the largest share of the AI in Drug Discovery Market at approximately 62%, driven by platform adoption across preclinical and clinical phases.
  • Service-based delivery is growing at a CAGR of 26.1%, reflecting the shift toward managed AI analytics among mid-tier pharmaceutical companies.

• By Technology

  • Machine learning holds the dominant position in the AI in Drug Discovery Market, representing a 28.2% CAGR through 2035.
  • Natural language processing and computer vision applications are gaining traction in literature mining and histopathology analysis.

• By Region

  • North America generated approximately USD 1.18 billion in 2025 revenue, maintaining its lead across the AI in Drug Discovery Market.
  • Asia-Pacific is projected to reach USD 6.21 billion by 2035, representing the fastest regional expansion trajectory.

 

AI in Drug Discovery Market Size and Forecast (2021–2035)

Market sizing draws on primary interviews with 42 pharmaceutical R&D executives, CRO leaders, and AI-platform vendors, supplemented by secondary analysis of SEC filings, clinical trial registries, and patent databases. Historical figures (2021–2024) reflect audited revenue, while the forecast (2026–2035) uses a bottom-up build anchored in platform licensing, service contracts, and internal deployment spend.

AI Drug Discovery Market Size and Forecast
Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Driver Impact Analysis

Driver ~% Impact on CAGR Geographic Relevance Impact Timeline
Escalating drug development costs +4.2% Global Short-term (≤2 yr)
Exponential growth in biomedical data +3.8% Global Medium-term (2–4 yr)
Government AI-healthcare funding programs +3.1% North America, Asia-Pacific Short-term (≤2 yr)
Pharma-AI strategic partnerships +3.5% North America, Europe Medium-term (2–4 yr)
Advances in transformer architectures for molecular generation +2.9% Global Long-term (≥4 yr)
Regulatory openness to AI-assisted submissions +2.4% North America, Europe Medium-term (2–4 yr)
Pandemic-era urgency for rapid drug repurposing +1.8% Global Short-term (≤2 yr)

 

Escalating Drug Development Costs

From USD 2.23 billion in 2024 to roughly USD 2.67 billion in 2025, the average cost to advance a medicine from discovery to launch has been steadily increasing. A high-stakes pipeline environment where concentration in a few "mega-blockbuster" products raises portfolio risk exacerbates this growing tendency. By cutting preclinical timelines—typically by 30–40%—AI platforms are being used more frequently to reduce these risks and offer a crucial way to increase pharmaceutical R&D's return on investment.

 

Exponential Growth in Biomedical Data

Thanks to developments in proteomics, genomics, and empirical evidence, the amount and complexity of biological data are growing at a rate never seen before. Large, excellent, AI-ready datasets that form the basis of machine learning models are being produced by the NIH's All of Us Research Program and related international programs. Because the success of de novo drug creation and more accurate target predictions are strongly correlated with the ability to combine different omic information and digital pathomics, AI platforms thrive on this data richness.

 

Government AI-Healthcare Funding Programs

The U.S. National Institutes of Health allocated USD 1.8 billion to AI-related health research grants during fiscal year 2024, a 34% increase from the prior year [9]. China's Ministry of Science and Technology committed RMB 12 billion (approximately USD 1.7 billion) to its AI-pharma industrial development plan through 2027. These public-sector commitments de-risk private investment and accelerate adoption within the AI in Drug Discovery Market.

Pharma-AI Strategic Partnerships

Between 2022 and 2024, over 180 strategic partnerships were signed between top-20 pharmaceutical companies and AI-native drug discovery firms, with total deal value exceeding USD 5.8 billion [3]. Sanofi's USD 1.2 billion multi-year collaboration with Insilico Medicine and AstraZeneca's partnership with Absci exemplify how these alliances create recurring revenue streams for AI platform providers and expand the AI in Drug Discovery Market.

 

Restraints Impact Analysis

Restraint estimates below reflect directional drag on growth and were modeled independently through scenario analysis. They do not net algebraically against the drivers listed in Section 4.

Restraint ~% Impact on CAGR Geographic Relevance Impact Timeline
Data quality and standardization gaps –2.8% Global Medium-term (2–4 yr)
Regulatory uncertainty for AI-derived therapeutics –2.3% Europe, Asia-Pacific Long-term (≥4 yr)
High platform implementation and integration costs –1.9% Global Short-term (≤2 yr)
Shortage of interdisciplinary AI-pharma talent –1.6% Global Medium-term (2–4 yr)
Intellectual property ambiguity around AI-generated molecules –1.2% North America, Europe Long-term (≥4 yr)

 

Data Quality and Standardization Gaps

Pharmaceutical datasets are still dispersed between academic repositories and corporate databases, frequently experiencing inconsistent annotation and technical "batch effects." The industry is realizing more and more that the quality of input data is a basic limitation on the performance of AI models. Strong data governance and provenance standards are essential for model reliability and cross-institutional reproducibility, making the shift to FAIR (Findable, Accessible, Interoperable, Reusable) data infrastructure a strategic imperative.

 

Regulatory Uncertainty for AI-Derived Therapeutics

The regulatory environment has developed considerably by 2026. The Guiding Principles of Good AI Practice in Drug Development, a formal, risk-based framework for AI-led discovery and clinical development, were jointly released by the FDA and EMA. This milestone shifts the industry's focus to "how" AI-derived candidates are vetted, eliminating any doubt about their acceptability. In order to comply with international GxP requirements, sponsors must now prove that their AI systems are "fit for purpose," which calls for thorough validation, documentation, and human-in-the-loop supervision.

 

High Implementation and Integration Costs

Deploying enterprise-grade AI discovery platforms requires USD 2–8 million in upfront infrastructure and integration work, including GPU cluster provisioning, data-lake construction, and workflow API development [14]. For companies outside the top-50 pharma tier, this capital barrier limits access and slows expansion of the AI in Drug Discovery Market into the long-tail of smaller drug developers.

 

AI in Drug Discovery Market Opportunities

AI-Powered Rare Disease Drug Discovery

Approximately 7,000 known rare diseases affect 300 million people globally, yet fewer than 5% have approved treatments [17]. AI platforms can repurpose existing compound libraries and identify novel targets in orphan indications at a fraction of traditional R&D cost, opening a high-margin niche within the AI in Drug Discovery Market.

Emerging Market Expansion in India and China

India's pharmaceutical sector exported USD 27.9 billion in formulations during FY2024, yet domestic AI adoption in drug discovery remains below 12% [18]. China's biopharma sector is investing heavily in AI-native startups, with over 60 AI-drug discovery firms founded since 2021. Both markets represent significant greenfield opportunity for platform vendors.

AI-as-a-Service Platforms for Mid-Tier Pharma

Cloud-native, subscription-based AI discovery platforms are lowering the entry barrier for companies with limited computational infrastructure. These SaaS models — priced between USD 200,000 and USD 1.5 million annually — allow mid-tier firms to access state-of-the-art generative chemistry without building in-house capabilities, expanding the addressable base of the AI in Drug Discovery Market.

Multi-Omics Data Integration

The convergence of genomics, proteomics, metabolomics, and real-world clinical data creates training sets that dramatically improve target validation accuracy. Platforms integrating three or more omic layers report 40% higher hit rates in virtual screens compared to single-omic approaches [19]. This integration trend will drive premium pricing and platform differentiation.

AI in Biologics and Cell-and-Gene Therapy Design

While small molecules dominate current AI-discovery applications, biologics represent a USD 450 billion global market with high unmet computational needs. Predictive molecular modeling for antibody and CAR-T optimization is an early-stage but fast-growing application area that could reshape competitive dynamics.

 

AI in Drug Discovery Market Future Outlook

Autonomous Discovery Loops

By 2030, fully autonomous discovery loops — where AI systems design, synthesize, test, and iterate on molecular candidates without human intervention between cycles — will move from academic proof-of-concept to commercial deployment. The AI in Drug Discovery Market will shift from tool-augmented workflows to agent-driven pipelines, with Recursion Pharmaceuticals and Insilico Medicine already operating semi-autonomous wet-lab-robotic platforms [20].

Foundation Models for Biology

Large-scale biological foundation models, trained on protein-structure databases, gene-expression atlases, and chemical-interaction graphs, will become the infrastructure layer for discovery. These models — analogous to GPT-class systems in language — will enable zero-shot predictions of drug-target interactions and dramatically shorten hit-to-lead timelines across the AI in Drug Discovery Market [10].

Regulatory Co-Evolution

Regulatory agencies will increasingly co-develop AI-specific submission frameworks with industry. The FDA's Artificial Intelligence/Machine Learning Action Plan and the EMA's draft reflection paper on AI in medicinal products are early indicators. By 2032, at least five major jurisdictions are expected to have binding AI-drug approval guidelines, reducing the regulatory friction that currently constrains the AI in Drug Discovery Market [13].

Platform Consolidation and Vertical Integration

The current landscape of 200+ point-solution vendors will consolidate into 15–20 end-to-end discovery platforms through M&A and strategic acquisitions. Large pharmaceutical companies will acquire AI-native firms to build vertically integrated R&D stacks, driving a consolidation wave in the AI in Drug Discovery Market valued at an estimated USD 8–12 billion in cumulative deal activity by 2035 [21].

 

AI in Drug Discovery Market Segmentation

By Component

Segment Share (2025) Primary Demand Driver
Software 62% Platform licensing for virtual screening and molecular generation
Service 38% Managed analytics and consulting for pharma R&D teams

 

Software dominates the AI in Drug Discovery Market by component, as pharmaceutical companies invest heavily in integrated discovery platforms that combine molecular simulation, hit identification, and ADMET prediction. Leading platforms like Schrödinger's LiveDesign and Insilico Medicine's Pharma.AI generate recurring SaaS revenue. The service segment is growing rapidly as mid-tier companies outsource AI model development and data curation to specialized vendors rather than building capabilities internally.

By Technology

Segment CAGR (2026–2035) Primary Demand Driver
Machine Learning 28.2% Deep learning for protein structure prediction and binding affinity
Natural Language Processing 22.6% Biomedical literature mining and adverse-event extraction
Computer Vision 21.4% Histopathology image analysis and high-content screening
Other AI Technologies 20.8% Reinforcement learning for molecular optimization

 

Machine learning is the backbone technology of the AI in Drug Discovery Market, powering applications from AlphaFold-style protein-structure prediction to generative adversarial networks for de novo molecular design. Deep-learning architectures — particularly graph neural networks and transformer models — have demonstrated the ability to reduce virtual screening false-positive rates by up to 60% compared to traditional docking methods [10].

By Application

Segment Share (2025) Primary Demand Driver
Target Identification & Validation 34% Multi-omic data integration for novel target discovery
Hit & Lead Generation 27% Generative chemistry and virtual screening
Preclinical Development 22% ADMET prediction and toxicity modeling
Clinical Trial Optimization 17% Patient stratification and site selection

 

Target identification and validation represents the largest application segment within the AI in Drug Discovery Market, reflecting the industry's prioritization of de-risking the earliest and most failure-prone stages of the pipeline. AI platforms analyze multi-omic datasets to surface druggable targets with higher confidence scores than traditional approaches.

By Drug Type

Segment CAGR (2026–2035) Primary Demand Driver
Small Molecule 23.4% Established compound libraries and screening infrastructure
Biologic 26.8% Antibody engineering and protein-design complexity
Other (RNA, Peptide) 25.1% Emerging modalities with high computational requirements

 

Biologic represented approximately 26.8% of the global AI in Drug Discovery Market in 2024, driven by growing investments in antibody therapeutics, cell and gene therapies, and AI-enabled protein engineering for complex biologic drug development. Other (RNA, Peptide): Accounted for approximately 25.1% of the global AI in Drug Discovery Market in 2024, supported by increasing research into RNA-based therapeutics, peptide drugs, and AI-assisted design of next-generation precision medicines.

 

By Deployment

Segment Share (2025) Primary Demand Driver
Cloud-Based 64% Scalability, collaboration, lower upfront cost
On-Premise 36% Data security requirements, IP protection

 

Cloud-based deployment leads the AI in Drug Discovery Market as pharmaceutical companies increasingly favor elastic compute resources for large-scale molecular simulations. On-premise solutions remain preferred by top-10 pharma companies with strict data-sovereignty requirements.

 

Regional Market Share Analysis

Region Share of Global Market (2025) Primary Investment Themes
North America 42% NIH AI grants, biotech startup density, FDA digital health pathway
Europe 28% UK life-sciences strategy, Horizon Europe funding, EMA adaptive pathways
Asia-Pacific 19% China's AI-pharma industrial plan, India CRO expansion, Japan regenerative medicine
South America 6% Brazil clinical-trial hub growth, regional CRO partnerships
Middle East & Africa 5% UAE health-tech free zones, Saudi Vision 2030 biotech investments
Total 100% —

The AI in Drug Discovery Market exhibits distinct regional dynamics, with established pharma ecosystems in North America and Europe driving current revenue, while Asia-Pacific captures the fastest growth trajectory.

 

North America

Country CAGR (2026–2035) Key Driver
United States 23.1% NIH funding, biotech cluster density
Canada 24.8% Federal AI strategy, academic-pharma linkages
Mexico 26.3% CRO nearshoring, regulatory harmonization

 

The United States anchors North America's dominance in the AI in Drug Discovery Market, with the Boston-Cambridge corridor and San Francisco Bay Area housing over 65% of venture-funded AI-pharma startups. Canada's Pan-Canadian AI Strategy committed CAD 443 million to applied health-AI research through 2028, while Mexico is emerging as a nearshore clinical-trial destination with AI-enabled site selection tools [9].

Europe

Country Share of Regional Market Key Driver
Germany 22% BioNTech-led AI integration, Fraunhofer institutes
United Kingdom 26% Life Sciences Vision 2030, Dementia Discovery Fund
France 18% Health Data Hub, Institut Pasteur collaborations
Italy 11% Pharmaceutical manufacturing AI retrofits
Spain 8% Hospital-linked clinical AI initiatives
Nordic Countries 9% Precision medicine registries, population biobanks
Russia 3% Domestic pharma AI pilots
Rest of Europe 3% —

 

The UK leads Europe's AI in Drug Discovery Market with its Life Sciences Vision committing GBP 1.6 billion to digital health R&D infrastructure and a regulatory sandbox for AI-derived therapies administered through the MHRA [5]. Germany's strength lies in mRNA-platform companies integrating AI into vaccine and oncology pipelines, while France's Health Data Hub centralizes anonymized patient records for AI model training across 120 partner institutions.

Asia-Pacific

Country CAGR (2026–2035) Key Driver
China 28.6% Government industrial policy, domestic AI-pharma startups
India 29.1% CRO ecosystem, BIRAC funding
Japan 22.4% AMED regenerative medicine AI programs
South Korea 25.7% Samsung Biologics AI investments, KIST partnerships
ASEAN 24.3% Clinical-trial diversification, digital health corridors
Rest of Asia-Pacific 23.8% —

 

Asia-Pacific represents the fastest-growing region within the AI in Drug Discovery Market, propelled by China's 14th Five-Year Plan allocation of RMB 12 billion for AI-driven biopharmaceutical innovation and India's Biotechnology Industry Research Assistance Council (BIRAC) grants totaling USD 280 million since 2022 [18]. Japan's AMED agency has earmarked JPY 90 billion for AI-augmented drug discovery in neurodegenerative diseases through 2030.

South America

Country Share of Regional Market Key Driver
Brazil 58% Anvisa modernization, clinical-trial hub status
Argentina 24% Academic bioinformatics programs
Rest of South America 18% —

 

Brazil dominates South America's share of the AI in Drug Discovery Market, driven by Anvisa's digital-first regulatory modernization and a growing network of AI-enabled clinical-trial sites serving multinational sponsors. Argentina contributes academic bioinformatics talent through programs at the University of Buenos Aires and CONICET.

Middle East & Africa

Country CAGR (2026–2035) Key Driver
Saudi Arabia 27.2% Vision 2030 biotech cluster, KAUST research
UAE 28.9% Dubai Health Authority AI sandbox, free-zone incentives
South Africa 22.6% Infectious disease AI research platforms
Egypt 23.4% Generics industry AI pilots
Rest of MEA 21.8% —

 

The UAE leads Middle East & Africa adoption within the AI in Drug Discovery Market through the Dubai Health Authority's AI regulatory sandbox and Abu Dhabi's G42 Healthcare investments. Saudi Arabia's NEOM biotech cluster and KAUST's computational biology center are expected to catalyze regional growth through 2035.

 

AI Drug Discovery Market By Region, 2025-2035

Competitive Benchmarking

The AI in Drug Discovery Market exhibits medium concentration with an estimated HHI of approximately 850, indicating a competitive but not fragmented structure. The top five companies hold a combined estimated share of 28–35%, while the long tail of 200+ startups and niche vendors creates a dynamic innovation ecosystem.

Company Est. Revenue Share Range Key Offerings Strategic Positioning
Insilico Medicine ~5–8% Pharma.AI platform, generative chemistry, clinical pipeline End-to-end discovery, first AI-designed drug in Phase II
Schrödinger ~5–7% LiveDesign, FEP+ free-energy perturbation, physics-based ML Hybrid physics-AI platform leader
Recursion Pharmaceuticals ~4–7% Recursion OS, automated wet-lab screening, phenomics Autonomous lab-AI integration
Exscientia ~3–6% Centaur Chemist, precision oncology pipeline AI-human hybrid design philosophy
BenevolentAI ~3–5% Benevolent Platform, knowledge graph-driven target ID Knowledge-centric approach to discovery
Atomwise ~2–4% AtomNet, convolutional neural network virtual screening Largest virtual screening dataset
AbCellera Biologics ~2–4% High-throughput antibody discovery, AI-guided selection Biologics-focused AI platform
NVIDIA ~3–5% Clara Discovery, BioNeMo, GPU-accelerated molecular simulation Infrastructure and enablement layer
Google DeepMind ~2–4% AlphaFold, protein-structure databases Foundational research, open-access tools
Absci Corporation ~1–3% Drug and target AI, integrated antibody design De novo antibody generation

 

 

Recent News & Developments

 

 

 

 

 

 

  • BenevolentAI (August 2023): Initiated Phase I trials for BEN-8744, an AI-identified PDE10 inhibitor for ulcerative colitis, representing the company's first wholly AI-discovered candidate entering clinical development [24].
  • January 2026: NVIDIA and Eli Lilly and Company announced the creation of a first-of-its-kind AI co-innovation lab with the goal of using AI to address some of the pharmaceutical industry's most persistent problems.
  • January 2026, NVIDIA announced a significant extension of NVIDIA BioNeMo, an open development platform that allows lab-in-the-loop operations to create innovations in drug discovery and AI-driven biology.
  • In Dec-22, IBM (US) acquired AlchemyAPI (US) a startup to bring deep learning to Watson. The goal is to use AlchemyAPI's resources to boost the ""cognitive"" computer system IBM Watson's intelligence.
  • In Aug-22, Atomwise Inc. signed a strategic multi-target research collaboration with Sanofi (France) for ai-powered drug discovery to leverage its AtomNet platform for computational discovery and research of up to five drug targets.
  • In Nov-21, Alphabet Inc. (US) has launched a new company Isomorphic Laboratories (UK), that aims to use artificial intelligence for drug discovery. The company will leverage that success to build tools that can help identify new pharmaceuticals.

 

 

AI in Drug Discovery Market Report Scope

Parameter Details
Market Scope AI software, services, and platforms used across the pharmaceutical and biotech drug discovery pipeline
Study Period 2021–2035
CAGR 23.9% (2026–2035)
Base Year Market Size USD 2.81 Billion (2025)
Forecast Endpoint USD 23.95 Billion (2035)
Fastest Growing Segment Machine Learning (by technology); Biologics (by drug type); Asia-Pacific (by region)
Companies Profiled 10
Valuation Currency USD

 

 

FAQs

How does AI reduce clinical-stage attrition rates compared to conventional screening?
AI platforms improve target validation accuracy by layering multi-omic evidence, cutting Phase I-to-approval failure rates by an estimated 20–30% [12]. This translates to hundreds of millions in recovered R&D investment per program.
What minimum data infrastructure does a mid-tier pharma company need before adopting AI discovery platforms?
A curated compound-activity database of at least 500,000 annotated records, a cloud-compute environment with GPU access, and a dedicated bioinformatics team of 3–5 specialists form the practical baseline [14].
How do intellectual property frameworks apply to AI-generated molecular structures?
Most jurisdictions currently require a human inventor on patent filings, creating ambiguity for fully AI-generated candidates [16]. Companies typically assign inventorship to the supervising chemist.
Which therapeutic areas show the highest ROI from AI-driven discovery investments?
Oncology and rare diseases deliver the strongest returns, with AI-discovered oncology candidates reaching clinical stages 40% faster and orphan drugs commanding premium pricing [17].
How do cloud-based and on-premise AI deployment models compare on data security for proprietary compound libraries?
On-premise installations offer tighter IP control but cost 3–5x more in infrastructure [14]. Cloud vendors now offer private-tenancy options with SOC 2 and HIPAA compliance that satisfy most pharma security audits.
What role do CROs play in the AI in Drug Discovery Market value chain?
CROs serve as integration partners, embedding AI tools into outsourced screening and preclinical workflows [3]. This lowers adoption barriers for sponsors without in-house AI capabilities.
How will foundation models for biology reshape competitive positioning in the AI in Drug Discovery Market by 2030?
Foundation models will commoditize basic prediction tasks, shifting differentiation toward proprietary training data and wet-lab validation capabilities [10]. Companies lacking unique datasets will face margin compression.    
Author
Author
Author Profile
Kinjoll Dey LinkedIn
Senior Research Analyst
He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Co-Author
Co-Author Profile
Vikita Thakur LinkedIn
Senior Research Analyst
She holds an experience of about 5+ years in market research and business consulting projects for sectors such as life sciences, medical devices, and healthcare IT. She possesses a robust background in data analysis, market estimation, competitive intelligence, pipeline analysis market trend identification, and consumer behavior insights. Her expertise lies in technical Sales support, client interaction and project management, designing and implementing market research studies, conducting competitive analysis, and synthesizing complex data into actionable recommendations that drive business growth.
Get In Touch

Research Approach

 

Secondary Research

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed scientific journals, clinical trial repositories, and authoritative health technology organizations. Key sources included the US Food & Drug Administration (FDA) Center for Drug Evaluation and Research, European Medicines Agency (EMA) Innovation Task Force, Pharmaceuticals and Medical Devices Agency (PMDA) Japan, National Medical Products Administration (NMPA) China, and Medicines and Healthcare products Regulatory Agency (MHRA) UK. Clinical trial activity was monitored through ClinicalTrials.gov, EU Clinical Trials Register (EudraCT), and WHO International Clinical Trials Registry Platform (ICTRP). Scientific literature was sourced from PubMed/MEDLINE, IEEE Xplore Digital Library, Nature Machine Intelligence, Journal of Chemical Information and Modeling, Cell Systems, and Briefings in Bioinformatics. Patent landscapes were analyzed via USPTO, European Patent Office (EPO), and WIPO databases. Industry and technology standards were reviewed through ISO/IEC JTC 1/SC 42 (Artificial Intelligence), FAIR Data Principles, and IEEE Standards Association. Institutional data was gathered from National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS), European Molecular Biology Laboratory-European Bioinformatics Institute (EMBL-EBI), Broad Institute, and Scripps Research. Investment and competitive intelligence was tracked through PitchBook, CB Insights, Crunchbase, and BCIQ (BioCentury Intelligence Quotient). Trade associations including Pharmaceutical Research and Manufacturers of America (PhRMA), Biotechnology Innovation Organization (BIO), European Federation of Pharmaceutical Industries and Associations (EFPIA), and Drug Information Association (DIA) provided regulatory and policy frameworks. These sources were used to collect AI algorithm adoption statistics, regulatory approval pathways for AI-driven drug candidates, clinical pipeline data, partnership and licensing transaction values, and technology landscape analysis across machine learning platforms, deep learning frameworks, natural language processing tools, and knowledge graph technologies.

 

Primary Research

To gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research phase. Supply-side sources included Vice Presidents of Discovery from AI-native drug discovery companies, pharmaceutical AI divisions, biotechnology companies, and computational platform providers, as well as Chief Executive Officers, Chief Technology Officers, Chief Data Officers, Heads of Artificial Intelligence/Machine Learning, and Chief Scientific Officers. Chief medical officers, heads of research and development, directors of global clinical operations, heads of translational medicine, data science leads, and heads of procurement from mid-cap biotechnology companies, academic medical centers, government research institutions, contract research organizations (CROs), and multinational pharmaceutical companies were among the demand-side sources. Primary research collected information on algorithm adoption trends, pharmaceutical partnership structures, licensing fee models, and regulatory submission strategies for AI-enabled drug discovery programs. It also verified AI platform development timelines and validated market segmentation across application areas.

Primary Respondent Breakdown:

• By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)

• By Region: North America (40%), Europe (25%), Asia-Pacific (28%), Rest of World (7%)

 

Market Size Estimation

Global market valuation was derived through revenue mapping and platform deployment analysis. The methodology included:

• Identification of 60+ key technology providers and AI-native drug discovery companies across North America, Europe, Asia-Pacific, and emerging markets

• Product mapping across machine learning, deep learning, natural language processing, knowledge graphs, and robotic process automation categories

• Analysis of reported and modeled annual revenues specific to AI drug discovery software platforms, computational chemistry tools, and predictive analytics suites

• Coverage of technology providers and pharmaceutical AI divisions representing 75-80% of global market share in 2024

• Extrapolation using bottom-up (number of active AI drug discovery programs × average contract value/platform licensing fees by therapeutic area) and top-down (technology provider revenue validation, pharmaceutical R&D AI spend allocation) approaches to derive segment-specific valuations across target identification, lead optimization, drug repurposing, clinical trial optimization, and preclinical testing workflows

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

Customer Stories

Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.